<DOC>
	<DOCNO>NCT00470522</DOCNO>
	<brief_summary>The treatment systemic lupus erythematosus ( SLE ) aim decrease mortality morbidity etiology disease unknown . The general aim multicentre randomize placebo-controlled trial low dose intermittent methotrexate folic acid establish whether methotrexate show efficacy safety control disease activity SLE preventing flare disease activity development end-organ damage . A second aim document steroid spar effect methotrexate SLE . A Third aim measure toxicity utility methotrexate folic acid perform effectiveness utility analysis .</brief_summary>
	<brief_title>Study Methotrexate Lupus Erythematosus</brief_title>
	<detailed_description>SLE chronic systemic autoimmune inflammatory disease . Approximately 65 % patient develop SLE 16 55 year age , 8-10 time common woman . Overall prevalence estimate 40-50 per 100,000 individual US . SLE typically include period remission flare . Systemic manifestation SLE include fatigue , fever , arthralgia , weight loss , skin rash . Disease progression variable unpredictable one individual next . Treatment aim preventing damage due inflammation involve tissue . Death occur primarily severe systemic infection renal insufficiency . Futhermore , patient long-standing SLE chronic steroid use may succumb atherosclerotic complication myocardial infarction . The mainstay treatment acute disease manifestation steroid , particular , prednisone . Once start , difficult reduce stop treatment without new flare severe steroid withdrawal . Longitudinal study SLE dissociate morbidity cause disease cause prolonged steroid use . Specific Objectives : 1 . To measure efficacy , safety tolerance methotrexate folic acid compare placebo folic acid . 2 . To measure steroid-sparing effect methotrexate SLE 3 . To perform cost-effectiveness cost-utility analysis methotrexate folic acid use generic disease specific health status measure . Qualification study : Once write informed consent obtain , subject screen visit laboratory evaluation perform determine qualify study . A patient enrol study eligibility criterion meet . No change dosage prednisone , NSAIDs plaquenil allow screen qualify visit . Assignment treatment : After qualify study , subject randomly assign receive one two treatment : placebo folic acid 2.5 mg/day except day take methotrexate placebo , methotrexate dos describe folic acid 2.5 mg/day except day whem methotrexate placebo take . Treatment period : All patient receive study medication ( placebo methotrexate ) least 12 month . If patient steroid , every effort do taper prednisone accord schedule . One flare require increase dose steroid high baseline ( dose determine local investigator ) allow . If second flare occur , mean stop trial . There open phase end trial respond favorably methotrexate placebo offer either continue start methotrexate 6 month . Drug formulation , route administration , dosage duration : Methotrexate : Patients randomly assign receive either methotrexate MTX-placebo ( except formulation placebo consist 44.00 mg lactose , 31.00 mg maize starch , 2.5 mg pregelatinized starch , 0.20 mg polysorbate 80 , 1.00 mg riboflavin , 20.70 mg microcrystalline cellulose , 1.50 mg magnesium stearate small quantity purify water sodium hydroxide 1N ) . It give orally . Each tablet contain 2.5 mg methotrexate equivalent color , size shape-matched placebo . Subject give 3 MTX tablet , 2.5 mg increment equivalent number MTX-placebo . Subjects ill give 3 MTX tablet , 2.5 mg.increment equivalent number MTX-placebo tablet take together week 12 month . If patient symptom , sign laboratory evidence toxicity 2 week , MTX increase 2.5 mg per 8 week interval maximal 0.25 mg/kg/week 20 mg/week achieve . In absence toxicity , MTX continue maximal tolerate dose 12 months.Dose adjust accord guideline MTX reduction toxicity . At end blind period , patient complete 12 month blind study , benefit MTX FA want continue try ( placebo ) offer continue open-label trial MTX FA . Folic Acid : Folic acid dose 2.5 mg/day 6 days/week give early patient . Folic acid give day methotrexate placebo take . folic acid vitamin know anti-inflammatory immunosuppressive activity dose know toxicity . Guidelines methotrexate dose reduction toxicity : Strict guideline define adjustment dose MTX placebo . In participate centre , physician review laboratory test adjust dose different physician ass disease activity clinical response treatment . Both physician blind study drug , do supplementary precaution protect blind blood test suggest patient placebo MTX . Open-label trial : Patient terminate study prematurely eligible receive treatment MTX follow-up study . The open trial model model protocol except blind . Patients receive MTX offer continuation drug surveillance mechanism extra 6 month . Those receive MTX-placebo offer try MTX . At end 6 month , open label trial terminate .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>men woman diagnosis SLE 18 year negative pregnancy test female subject childbearing age must accept attempt get pregnant period study Subject active disease define SLAM least 8 SLICC/ACR damage index less equal 15 Subject must stable NSAIDs , prednisone , antimalarial ( chloroquine sulfate hydroxychloroquine ) least 4 week precede study subject medication long condition treatment interfere experimental medication assessment must understand either French English give write informed consent previous history hypersensitivity intolerance methotrexate folic acid total SLAM le 8 total SLICC/ACR score 15. history medical noncompliance inability comply instruction subject receive intraarticular intramuscular corticosteroid four week prior study entry . clinically significant acute chronic liver disease exception autoimmune liver disease alcohol use excess 2 ounce 100 proof liquor equivalent/week insulin require diabetes mellitus morbid obesity renal impairment serum creatinine equal 175 umol/I ( SI unit ) 2.0 mg/dl interstitial lung disease define abnormal chest xray decrease diffusion capacity ( DLCO &lt; 70 % predict ) without evidence pulmonary hypertension . WBC count ,3,000/ cubic mm . and/or platelet count ,80,000/ cubic mm . prior use methotrexate treat SLE use sulfa drug may potentiate folate antagonistic effect MTX nonsteroidal antiinflammatory drug allow throughout trial unless evidence renal failure contraindication drug . Their concomitant use MTX routine patient rheumatoid arthritis . use another cytotoxic immunosuppressive drug cyclophosphamide , azathioprine , chlorambucil , cyclosporin trimetoprime currently precede 6 month . current participation drug trial participation trial previous one month . serologic evidence infection HIV biologic potential pregnancy utilize effective mean contraception recently ( less 6 month ) diagnose malignancy vitamin B12 deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>methotrexate</keyword>
	<keyword>folic acid</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>steroid</keyword>
</DOC>